HIMS Hims & Hers Health, Inc.
Stock · NYSE · United States · Healthcare · US4330001060
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Hims & Hers Health, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:27. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 09 Nov 2026 16:00 | 0.06 | — | — | Upcoming |
| 10 Aug 2026 16:00 | -0.05 | -0.37 | -640.0% | Miss |
| 11 May 2026 16:00 | 0.13 | -0.19 | -244.0% | Miss |
| 23 Feb 2026 16:00 | 0.19 | 0.22 | +20.8% | Beat |
| 03 Nov 2025 16:00 | 0.23 | 0.28 | +20.4% | Beat |
| 04 Aug 2025 16:00 | 0.23 | 0.29 | +26.3% | Beat |
| 05 May 2025 16:00 | 0.23 | 0.28 | +24.2% | Beat |
| 24 Feb 2025 16:00 | 0.22 | 0.23 | +4.2% | Beat |
| 04 Nov 2024 16:00 | 0.15 | 0.43 | +187.4% | Beat |
| 05 Aug 2024 16:00 | 0.13 | 0.16 | +28.6% | Beat |
| 06 May 2024 16:00 | 0.08 | 0.10 | +22.5% | Beat |
| 26 Feb 2024 16:00 | 0.06 | 0.05 | -16.1% | Miss |
| 06 Nov 2023 16:00 | 0.05 | 0.06 | +0.3% | In line |
| 07 Aug 2023 16:00 | 0.03 | 0.05 | +72.3% | Beat |
| 08 May 2023 16:00 | 0.02 | 0.03 | +45.5% | Beat |
| 27 Feb 2023 16:00 | -0.06 | -0.05 | +13.6% | Beat |
| 07 Nov 2022 16:00 | -0.06 | -0.09 | -49.9% | Miss |
| 08 Aug 2022 16:00 | -0.06 | -0.10 | -68.7% | Miss |
| 09 May 2022 16:00 | -0.06 | -0.08 | -43.0% | Miss |
| 22 Feb 2022 16:00 | -0.06 | -0.10 | -58.2% | Miss |
| 10 Nov 2021 16:00 | -0.06 | -0.10 | -59.6% | Miss |
| 11 Aug 2021 16:00 | -0.06 | -0.09 | -58.7% | Miss |
| 17 May 2021 07:00 | -0.07 | -0.28 | -330.3% | Miss |
| 18 Mar 2021 16:00 | -0.06 | -0.05 | +11.5% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 2.3B | +59.0% | 128.4M | 5.5% | 0.51 | -3.8% | 57.4M |
| 2024 | 1.5B | +69.3% | 126M | 8.5% | 0.53 | +581.8% | 198.3M |
| 2023 | 872M | +65.5% | -23.5M | -2.7% | -0.11 | +65.6% | 47M |
| 2022 | 526.9M | — | -65.7M | -12.5% | -0.32 | — | -33.8M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 13 Dec 2024 | 29.72 | 30.60 | 28.40 | 30.02 | -0.23% | 7,944,400 | |
| 12 Dec 2024 | 30.20 | 32.22 | 30.09 | 30.09 | -0.33% | 8,481,300 | |
| 11 Dec 2024 | 30.51 | 30.51 | 28.72 | 30.19 | -2.20% | 13,123,900 | |
| 10 Dec 2024 | 32.25 | 32.30 | 29.68 | 30.87 | -5.39% | 14,460,600 | |
| 09 Dec 2024 | 34.30 | 34.86 | 32.60 | 32.63 | -4.67% | 10,909,200 | |
| 06 Dec 2024 | 32.64 | 34.50 | 31.00 | 34.23 | +8.32% | 13,460,700 | |
| 05 Dec 2024 | 33.10 | 34.88 | 31.54 | 31.60 | -6.84% | 14,224,400 | |
| 04 Dec 2024 | 32.00 | 34.41 | 31.90 | 33.92 | +5.31% | 14,816,300 | |
| 03 Dec 2024 | 31.29 | 33.93 | 30.77 | 32.21 | +4.41% | 13,983,300 | |
| 02 Dec 2024 | 33.56 | 33.99 | 30.72 | 30.85 | -4.25% | 15,623,300 | |
| 29 Nov 2024 | 30.24 | 32.65 | 29.80 | 32.22 | +6.20% | 10,258,600 | |
| 27 Nov 2024 | 31.49 | 35.02 | 30.03 | 30.34 | -1.11% | 24,738,800 | |
| 26 Nov 2024 | 29.90 | 31.68 | 29.37 | 30.68 | -2.14% | 19,613,600 | |
| 25 Nov 2024 | 26.49 | 31.40 | 26.37 | 31.35 | +23.77% | 49,446,700 | |
| 22 Nov 2024 | 23.72 | 25.37 | 23.03 | 25.33 | +4.89% | 17,465,100 | |
| 21 Nov 2024 | 21.90 | 24.58 | 21.36 | 24.15 | +10.83% | 24,054,400 | |
| 20 Nov 2024 | 23.05 | 23.12 | 21.44 | 21.79 | -7.39% | 18,420,500 | |
| 19 Nov 2024 | 20.58 | 23.64 | 20.02 | 23.53 | +12.10% | 22,845,300 | |
| 18 Nov 2024 | 19.50 | 21.92 | 19.29 | 20.99 | +8.64% | 23,562,200 | |
| 15 Nov 2024 | 21.33 | 21.38 | 19.15 | 19.32 | -7.34% | 32,409,600 | |
| 14 Nov 2024 | 24.08 | 25.45 | 20.21 | 20.85 | -24.46% | 62,791,600 | |
| 13 Nov 2024 | 29.12 | 30.44 | 27.51 | 27.60 | +3.41% | 21,430,900 | |
| 12 Nov 2024 | 26.46 | 28.37 | 26.16 | 26.69 | -4.27% | 15,916,200 | |
| 11 Nov 2024 | 24.80 | 29.68 | 24.39 | 27.88 | +19.09% | 38,534,700 | |
| 08 Nov 2024 | 23.60 | 23.61 | 21.41 | 23.41 | -0.89% | 17,983,800 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Hims & Hers Health (HIMS) Could Be 85% Undervalued Following The Eli Lilly Deal (opens in a new tab) Simply Wall St. · 07 Nov 2026 20:16
- Hims & Hers Stock After Lilly Weight Loss Drug Deal Has The Bull Case Changed? (opens in a new tab) Simply Wall St. · 07 Nov 2026 18:13
- Hims & Hers Health (HIMS) Adds FDA Approved Obesity Drugs To Its Platform (opens in a new tab) Simply Wall St. · 07 Nov 2026 17:11
- Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027? (opens in a new tab) Motley Fool · 07 Nov 2026 03:25
- Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly (opens in a new tab) Investor's Business Daily · 06 Nov 2026 21:11
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs (opens in a new tab) Investing.com · 06 Nov 2026 17:57
- Hims & Hers rises 5% as Eli Lilly deal brings $149 obesity pill access (opens in a new tab) Proactive · 06 Nov 2026 16:28
- HIMS' Q3 Earnings: Can Weight Loss Momentum Drive Performance? (opens in a new tab) Zacks · 06 Nov 2026 15:14
- Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement (opens in a new tab) Barrons.com · 06 Nov 2026 13:24
- Lilly to sell obesity drugs directly on Hims & Hers site (opens in a new tab) Reuters · 06 Nov 2026 13:22
- Eli Lilly Partners With Hims & Hers to Expand Access to Obesity Treatments Through Telehealth (opens in a new tab) InvestorsHub · 06 Nov 2026 12:51
- Hims & Hers Health (HIMS) Stock Looks Reasonable After Its 263% Run (opens in a new tab) Simply Wall St. · 06 Nov 2026 03:21
- Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today (opens in a new tab) Zacks · 05 Nov 2026 21:45
- Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know (opens in a new tab) Zacks · 29 Oct 2026 20:45
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 24.06 USD
- Market cap
- 6.1B
- Exchange
- NYSE
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 20.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 8.8 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 9.9 / 10 |
|
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 35.27× | Weak | 14.94× |
| Price / book | 18.72× | Weak | 3.81× |
| Price / sales | 2.35× | Fair | 3.19× |
| EV / EBITDA | -665.36× | Weak | 12.63× |
| Free cash flow yield | 14% | Good | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 69.5% | Good | 58.6% |
| Operating margin | -12.8% | Weak | 7.8% |
| Net margin | -5.5% | Weak | 2.8% |
| Return on equity | -32% | Weak | 5.7% |
| Return on assets | -2.2% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 64.5% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 4.77× | Weak | 0.48× |
| Current ratio | 0.93× | Weak | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow HIMS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.